These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 15926763)

  • 1. Tegaserod treatment for IBS: a model of indirect costs.
    Smith DG; Barghout V; Kahler KH
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S43-50. PubMed ID: 15926763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget impact of tegaserod on a managed care organization formulary.
    Bloom MA; Barghout V; Kahler KH; Bentkover J; Kurth H; Gralnek IM; Spiegel BM
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S27-34. PubMed ID: 15926761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacoeconomics and outcome research on Irritable Bowel Syndrome review of findings using Tegaserod].
    Ariza JG; Martínez JA
    Rev Gastroenterol Peru; 2006; 26(1):77-9. PubMed ID: 16622489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
    Reilly MC; Barghout V; McBurney CR; Niecko TE
    Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The economic consequences of irritable bowel syndrome: a US employer perspective.
    Leong SA; Barghout V; Birnbaum HG; Thibeault CE; Ben-Hamadi R; Frech F; Ofman JJ
    Arch Intern Med; 2003 Apr; 163(8):929-35. PubMed ID: 12719202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB; Wilhelm SM
    Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impairment in work productivity and health-related quality of life in patients with IBS.
    Dean BB; Aguilar D; Barghout V; Kahler KH; Frech F; Groves D; Ofman JJ
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S17-26. PubMed ID: 15926760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total costs of IBS: employer and managed care perspective.
    Cash B; Sullivan S; Barghout V
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S7-16. PubMed ID: 15926759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tegaserod in treatment of women with irritable bowel syndrome].
    Munck LK; Ainsworth MA
    Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
    Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA
    Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of tegaserod therapy on GI-related resource utilization in a managed care population.
    Stephenson JJ; Barghout V; Kahler KH; Fernandes J; Beaulieu JF; Joo S; Boccuzzi SJ
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S35-42. PubMed ID: 15926762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
    Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: tegaserod -- the global experience.
    Chey WD
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():15-9. PubMed ID: 15521850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The spectrum of irritable bowel syndrome: A clinical review.
    Gilkin RJ
    Clin Ther; 2005 Nov; 27(11):1696-709. PubMed ID: 16368443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome.
    Beglinger C
    Int J Clin Pract; 2002; 56(1):47-51. PubMed ID: 11831835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care.
    Layer P; Keller J; Mueller-Lissner S; Rüegg P; Loeffler H
    Digestion; 2005; 71(4):238-44. PubMed ID: 16024929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling the impact of enhanced depression treatment on workplace functioning and costs: a cost-benefit approach.
    Lo Sasso AT; Rost K; Beck A
    Med Care; 2006 Apr; 44(4):352-8. PubMed ID: 16565636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population.
    Guerin A; Carson RT; Lewis B; Yin D; Kaminsky M; Wu E
    J Med Econ; 2014 Aug; 17(8):577-86. PubMed ID: 24811855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study.
    Paré P; Gray J; Lam S; Balshaw R; Khorasheh S; Barbeau M; Kelly S; McBurney CR
    Clin Ther; 2006 Oct; 28(10):1726-35; discussion 1710-1. PubMed ID: 17157129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.